Melanoma

News and reporting on melanoma.

May 11, 2022

Castle Bio Adds New Outcome Data for Melanoma Assay, Shares Early Info on Skin Disease Test
Premium

May 10, 2022

OncoHost Raises $35M in Series C Financing

May 9, 2022

Castle Biosciences Q1 Revenues Grow 18 Percent

Apr 29, 2022

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

Mar 2, 2022

Castle Bio Adds Data for DecisionDx Melanoma Assay, Eyes Squamous Cell Carcinoma Reimbursement
Premium

Feb 28, 2022

Castle Biosciences Q4 Revenues Grow 45 Percent

Feb 3, 2022

Castle Biosciences Working With NCI on SEER Registry Study of DecisionDx-Melanoma

Dec 8, 2021

Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma

Sep 16, 2021

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Aug 24, 2021

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

May 14, 2021

DermTech Q1 Revenues up 62 Percent

May 10, 2021

Castle Biosciences Q1 Revenues Up 31 Percent

Mar 8, 2021

Castle Biosciences Q4 Revenues Down 2 Percent

Jan 28, 2021

DermTech Using $144M Financing to Spur Marketing, Telemedicine Efforts For Molecular Melanoma Assay
Premium

Jan 22, 2021

Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Jan 4, 2021

Castle Bio, NantHealth Pace Gainers as 360Dx Index Climbs 4 Percent in December

Dec 14, 2020

Craig-Hallum Initiates Coverage of DermTech With Buy Rating

Dec 3, 2020

Local Coverage Determinations Roundup: Castle Bio

Nov 9, 2020

Castle Biosciences Q3 Revenues Up 3 Percent

Nov 6, 2020

Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests